Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges.
Fiche publication
Date publication
octobre 2018
Journal
Gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
Tous les auteurs :
Baumert TF, Berg T, Lim JK, Nelson DR
Lien Pubmed
Résumé
Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma worldwide. Following the discovery of HCV 3 decades ago, the identification of the structure of the viral proteins, combined with high-throughput replicon models, enabled the discovery and development of direct-acting antivirals. These agents have revolutionized care of patients, with cure rates of more than 90%. We review the status of direct-acting antiviral therapies for HCV infection and discuss remaining challenges. We highlight licensed compounds, discuss the potential to shorten therapy even further, and review different options for treatment failure and resistance. We also provide an overview on clinical experience with generic agents and evidence for their efficacy. Finally, we discuss the need for new drugs and outline promising targets for future therapies.
Mots clés
Direct-Acting Antivirals, Hepatitis C, Resistance, Treatment Failure
Référence
Gastroenterology. 2018 Oct 17;: